Hungary is a mature Central European clinical trial market that consistently performs above its population size.
With a population of 9.6 million, more than 5,100 trials listed on ClinicalTrials.gov and a 60 day regulatory approval pathway, the country offers sponsors a strong mix of speed, quality and patient access.
Its clinical research ecosystem is anchored by Budapest, four elite medical universities, a centralized health insurance system and deep therapeutic strength across oncology, pulmonology, cardiology, gastroenterology and neurology. For sponsors, Hungary is especially valuable because it combines predictable startup, motivated patient populations, strong Phase I capability and proven rescue enrollment performance when multi country studies underperform.